Document 0241
 DOCN  M9440241
 TI    Quantitation of human immunodeficiency virus by culture and polymerase
       chain reaction in response to didanosine after long-term therapy with
       zidovudine.
 DT    9404
 AU    Katzenstein DA; Winters M; Bubp J; Israelski D; Winger E; Merigan TC;
       Center for AIDS Research, Stanford University Medical Center,;
       California.
 SO    J Infect Dis. 1994 Feb;169(2):416-9. Unique Identifier : AIDSLINE
       MED/94149331
 AB    Measurements of human immunodeficiency virus by quantitative RNA and DNA
       polymerase chain reaction (PCR), cell and plasma infectivity dilution
       cultures, and immune complex-disassociated p24 antigen-capture ELISA
       were made repeatedly in 10 subjects receiving long-term zidovudine
       treatment before and after therapy was changed to didanosine. Comparison
       of baseline assays showed that quantitative cell cultures, plasma RNA,
       and proviral DNA were measurable in all subjects and that cell culture
       results were significantly correlated with measures of nucleic acids.
       Plasma viremia (as indicated by culture) and p24 antigen were detected
       in three measurements in 3 of 8 and 6 of 10 subjects, respectively.
       Significant decreases in plasma RNA and cell dilution cultures from
       baseline were maintained for up to 6 months after initiation of
       didanosine therapy. These findings demonstrate a decrease in virus
       burden with the use of didanosine; however, continued detection of
       plasma RNA suggests that additional antiviral therapy will be required
       to suppress viral replication.
 DE    Adult  Didanosine/*ADMINISTRATION & DOSAGE  DNA, Viral/ANALYSIS  Human
       HIV Core Protein p24/ANALYSIS  HIV Infections/*DIAGNOSIS/DRUG
       THERAPY/MICROBIOLOGY  HIV Seropositivity/MICROBIOLOGY  Leukocyte Count
       Middle Age  Polymerase Chain Reaction  Proviruses/CHEMISTRY  RNA,
       Viral/ANALYSIS  Support, U.S. Gov't, P.H.S.  Time Factors  T4
       Lymphocytes  Zidovudine/*ADMINISTRATION & DOSAGE  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).